Nineteen Twenty-One
Venture CapitalFredrik Debong
Rewriting the future of type 1 diabetes care — backing the boldest innovations in metabolic health through specialized capital and unparalleled sector expertise.
About Nineteen Twenty-One.
The beauty of 1921 VC lies in its singular focus and founder-GP symbiosis. Fredrik's journey from patient to entrepreneur to investor has created a unique vantage point - he sees opportunities where others see obstacles and speaks the language of clinicians, regulators, and engineers with equal fluency. After building mySugr into a category leader and achieving one of Europe's landmark digital health exits, he refined his investment thesis through 26 angel investments that delivered a 4.6x MOIC in diabetes-focused companies.
Nineteen Twenty-One represents the crystallization of this experience into a disciplined investment vehicle. The fund targets pre-seed to Series A companies developing everything from AI-powered diagnostic tools to next-generation therapies. What truly differentiates 1921 VC is its embedded advantage. Fredrik has assembled what might be the world's most concentrated network of diabetes expertise - Roche alumni, UCSF researchers, FDA advisors, and patient advocates who become active participants in portfolio companies. When a startup needs to design a clinical trial, they access scientists who've run hundreds. When facing regulatory hurdles, they get counsel from those who've shaped policy. This isn't just capital - it's an entire ecosystem distilled into competitive advantage.
Nineteen Twenty-One represents a rare alignment of expertise and opportunity. With diabetes care at an inflection point - where AI, biotechnology, and patient-centered design are converging - the fund is positioned to back the next generation of category-defining companies. Fredrik's unique perspective as a patient, founder, and investor creates a distinct advantage in identifying and supporting teams that can translate innovation into real-world impact.
